Merck is attractively valued, boasting strong free cash flow, robust margins, and a leading position in oncology with Keytruda. MRK faces a looming patent cliff for Keytruda in 2028, but a strong late ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback